Breaking Finance News

A report released today by Zacks Investment Research about Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) bumps the target price to $5.75

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) had its price target upped to $5.75 by Zacks Investment Research in a report released Monday October 10, 2016. The new stock price target implies a possible upside of 0.25% based on the company's most recent stock price close.

Boasting a price of $4.59, Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) traded 10.89% higher on the day. With the last stock price close up 30.57% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. DRNA has recorded a 50-day moving average of $3.92 and a 200-day moving average of $3.90. 233,260 shares of DRNA traded, down from an avg. volume of 263,498

Recent Performance Chart

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Dicerna Pharmaceuticals Inc has with a one year low of $2.69 and a one year high of $15.93 and has a market capitalization of $0.

A total of 4 analysts have released a report on Dicerna Pharmaceuticals Inc. Three analysts rating the company a strong buy, one analyst rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $14.50.

General Company Details For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *